Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 7/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19498172 | 0.83 | MAPT (0.35) | LMNAPOLBMAPTTP53HSP90AB1 | |
| SCHEMBL17624380 | 0.82 | LMNA (0.39) | LMNAPOLBMAPTTP53HSP90AB1 | |
| SCHEMBL17624369 | 0.76 | LMNA (0.47) | LMNAPOLBMAPTTP53HSP90AB1 | |
| SCHEMBL17624443 | 0.75 | CCNC (0.41) | HTR3AHRH4 | |
| SCHEMBL17624125 | 0.73 | HSP90AB1 (0.50) | LMNAPOLBMAPTHSP90AB1HRH4 | |
| SCHEMBL17624370 | 0.73 | LMNA (0.39) | LMNAPOLBMAPTTP53HSP90AB1 | |
| SCHEMBL24920540 | 0.72 | LMNA (0.47) | LMNAPOLBMAPTTP53HSP90AB1 | |
| SCHEMBL24920524 | 0.71 | LMNA (0.39) | LMNAPOLBMAPTTP53HSP90AB1 | |
| SCHEMBL18430319 | 0.71 | ACACB (0.45) | ACACB | |
| SCHEMBL12840038 | 0.69 | HSP90AA1 (0.40) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-26 | — | — | US | disclosed |
| WO-2016044604-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, ADRM1, PRMT1 | LMNA 2796/4885POLB 1694/4885MAPT 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.